Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04606446
Recruitment Status : Not yet recruiting
First Posted : October 28, 2020
Last Update Posted : October 28, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib.

Condition or disease Intervention/treatment Phase
Locally Advanced or Metastatic ER+ HER2- Breast Cancer Locally Advanced or Metastatic Castration-resistant Prostate Cancer Locally Advanced or Metastatic Non-small Cell Lung Cancer Drug: PF-07248144 Drug: Fulvestrant Drug: Letrozole Drug: Palbociclib Phase 1

Detailed Description:

Study has two parts, Part 1 (dose escalation) and Part 2 (dose expansion). Part 1 is divided into Parts 1A, 1B, and 1C and Part 2 is divided into Parts 2A and 2B. In Part 1A, single escalating doses of PF-07248144 alone will be administered to determine the maximum tolerable dose (MTD) and select the recommended dose for expansion (RP2D). In Part 1B and 1C, PF-07248144 will be administered in combination with either fulvestrant or letrozole + palbociclib.

After the determination of the monotherapy expansion RP2D in Part 1A, PF-07248144 will be evaluated in a dose expansion cohort as a monotherapy in Part 2A. After determination of the combination RP2D from Part 1B and Part 1C, PF-07248144 in combination with an either fulvestrant (Part 1B) or letrozole + palbociclib (Part 1C) may be evaluated in Part 2B. The specific combination partners that will be carried forward to Part 2B will be contingent upon preclinical evidence, clinical safety and potential efficacy as well as PK and PD data.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The dose escalation parts and the dose finding parts of the study will be guided by a Bayesian analysis of Cycle 1 dose-limiting toxicity (DLT) data for PF-07248144 as monotherapy or in combination with fulvestrant or with letrozole + palbociclib. A traditional 2-parameter Bayesian Logistic Regression Model (BLRM) will be used to model the DLT relationship of PF-07248144 monotherapy and a more complex BLRM model specifically designed for combinations will be used to model the dose toxicity relationship of PF-07248144 given in combination with fulvestrant or with letrozole + palbociclib.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.
Estimated Study Start Date : November 8, 2020
Estimated Primary Completion Date : September 6, 2024
Estimated Study Completion Date : February 8, 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1A Monotherapy Escalation Dose Level 1
PF-07248144 Monotherapy Escalation
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 1A Monotherapy Escalation Dose Level 2
PF-07248144 Monotherapy Escalation
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 1A Monotherapy Escalation Dose Level 3
PF-07248144 Monotherapy Escalation
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 1A Monotherapy Escalation Dose Level 4
PF-07248144 Monotherapy Escalation
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 1B Combination Dose Finding Arm level 1
PF-07248144 with Fulvestrant Combination Dose Finding
Drug: PF-07248144
KAT6 Inhibitor

Drug: Fulvestrant
Endocrine Therapy
Other Name: Faslodex

Experimental: 1B Combination Dose Finding Arm Level 2
PF-07248144 with Fulvestrant Combination Dose Finding
Drug: PF-07248144
KAT6 Inhibitor

Drug: Letrozole
Endocrine Therapy
Other Name: Femara

Drug: Palbociclib
CDK4/6 Inhibitor
Other Name: Ibrance

Experimental: 1C Combination Dose Finding Arm Level 1
PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 1C Combination Dose FInding Arm Level 2
PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
Drug: PF-07248144
KAT6 Inhibitor

Drug: Fulvestrant
Endocrine Therapy
Other Name: Faslodex

Drug: Letrozole
Endocrine Therapy
Other Name: Femara

Drug: Palbociclib
CDK4/6 Inhibitor
Other Name: Ibrance

Experimental: 2A Monotherapy Dose Expansion Arm
PF-07248144 Monotherapy Dose Expansion
Drug: PF-07248144
KAT6 Inhibitor

Experimental: 2B Combination Dose Expansion Arm
PF-07248144 with either Fulvestrant or Letrozole + Palbociclib Dose Expansion
Drug: PF-07248144
KAT6 Inhibitor




Primary Outcome Measures :
  1. Number of participants with dose-limiting toxicities in the Dose Escalation Arms. [ Time Frame: Up to 29 days ]
    Dose-limiting toxicities (DLTs)

  2. Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms. [ Time Frame: Up to 24 months ]
    Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.

  3. Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms. [ Time Frame: Up to 24 months ]
    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

  4. Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
    Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.

  5. Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.


Secondary Outcome Measures :
  1. Single Dose: Maximum Observed Concentration (Cmax) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  2. Single Dose: Time to Maximum concentration (Tmax) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  3. Single Dose: AUC from time zero to time of last measurable concentration (AUClast) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  4. Single and Multiple Dose: Terminal Elimination half-life (t1/2) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  5. Multiple Dose: Steady-State Cmax (Cmax,ss) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  6. Multiple Dose: Steady-state Tmax (Tmax,ss) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  7. Multiple Dose: Steady state AUC during a dosage interval (τ) (AUCτ,ss) in the Dose Escalation and Dose Finding Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  8. Multiple Dose: Steady-state Cmin (Cmin,ss) in the Dose Escalation and Dose Finding Arms. [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  9. Multiple Dose: Steady-state apparent total clearance (CLss/F) in the Dose Escalation and Dose Finding Arms. [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessments for PF-07248144

  10. Best Overall Response (BOR) in participants in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
  11. Duration of Response (DOR) in participants enrolled in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
  12. Peak concentrations of PF-07248144 for selected cycles in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessment for PF-07248144

  13. Trough concentrations of PF-07248144 for selected cycles in the Dose Escalation Arms [ Time Frame: Up to 24 months ]
    Pharmacokinetic (PK) assessment for PF-07248144

  14. Maximum Observed Concentration (Cmax) in the participants in the food effect subset in monotherapy dose expansion arm [ Time Frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days) ]
    The effect of food on the PK of PF-07248144.

  15. Time to Maximum concentration (Tmax) in the participants in the food effect subset in monotherapy dose expansion arm [ Time Frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days) ]
    The effect of food on the PK of PF-07248144.

  16. AUC from time zero to time of last measurable concentration (AUClast) in the participants in the food effect subset in monotherapy dose expansion arm [ Time Frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days) ]
    The effect of food on the PK of PF 07248144.

  17. Progression Free Survival (PFS) observed in participants in the Dose Expansion Arms [ Time Frame: Up to 24 months ]
  18. Time to Progression (TTP) observed in participants enrolled in the Dose Expansion Arms [ Time Frame: Up to 24 months ]
  19. Overall survival (OS) observed in participants enrolled in Dose Expansion Arms [ Time Frame: Up to 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Disease Characteristics - Breast, Prostate, and Lung Cancer

    • Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer, locally advanced or metastatic CRPC, or locally advanced or metastatic NSCLC that is intolerant or resistant to standard therapy or for which no standard therapy is available.
    • Part 1B and Part 1C (Combination Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting.
    • Part 2A (ER+HER2- breast cancer 3L+, monotherapy) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of CDK4/6 inhibitor and 2 lines of endocrine therapy.
    • Part 2B (ER+HER2- breast cancer 2L, combination) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after first line combination treatment with letrozole + palbociclib.
    • Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of ER-positive tumor (≥1% positive stained cells) based on most recent tumor biopsy utilizing an assay consistent with local standards.
    • Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of HER2-negative tumor: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.
    • Female participants with ER+HER2- advanced or metastatic breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause by treatment with the approved LHRH agonist such as goserelin, leuprolide or equivalent agents to induce chemical menopause.
    • Participants must have at least 1 measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated.
    • Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1
    • Female or male patients aged ≥ 18 years (Japan ≥ 20 years).
    • Adequate renal, liver, and bone marrow function.
    • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment.

Exclusion Criteria:

  • Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites require review by sponsor's medical monitor).
  • Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks prior to study entry.
  • Prior irradiation to >25% of the bone marrow.
  • ECG clinically relevant abnormalities (eg, QTc >470 msec, complete LBBB, second/third degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia).
  • Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin K antagonists or factor Xa inhibitors may be allowed following discussion with the Sponsor.
  • Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of PF-07248144.
  • Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux disease under treatment is allowed.
  • Pregnant or breastfeeding female participants.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04606446


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Layout table for location information
United States, Texas
NEXT Oncology
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04606446    
Other Study ID Numbers: C4551001
First Posted: October 28, 2020    Key Record Dates
Last Update Posted: October 28, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Neoplasms by Site
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Letrozole
Fulvestrant
Palbociclib
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Protein Kinase Inhibitors